NCT01515592 - Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg

DRUG

liraglutide

One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks

DRUG

liraglutide

One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks

DRUG

placebo

Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo